Shire Says Patent Deals Didn't Block Generic Adderall

Law360, New York (June 10, 2013, 6:46 PM EDT) -- Shire US Inc. pushed a Florida federal judge on Friday to chuck a putative class action alleging it kept unbranded versions of wildly popular attention deficit disorder drug Adderall XR off the market, arguing that its settlements of patent litigation didn’t prevent generic competition.

Shire argued to U.S. District Judge Joan A. Lenard that buyers of the drug didn't suffer any antitrust injury from deals its struck with two generic rivals that allegedly kept new Adderall versions offline for three years, since none of the manufacturers...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.